Anzeige
Mehr »
Mittwoch, 22.04.2026 - Börsentäglich über 12.000 News
Diese Aktie zündet die nächste Explorationsstufe - und der Markt beginnt aufzuwachen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40NJY | ISIN: CA23256X4075 | Ticker-Symbol: R7E
Tradegate
22.04.26 | 11:39
4,370 Euro
+3,31 % +0,140
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CYBIN INC Chart 1 Jahr
5-Tage-Chart
CYBIN INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,2554,40013:27
4,2554,39013:27

Aktuelle News zur CYBIN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiCybin Inc (2): Cybin cheers Executive Order on psychedelic research12
DiCybin Inc (2): Cybin CEO Cola resigns10
MoHelus Pharma CEO Michael Cola steps down; Eric So takes interim CEO role16
CYBIN Aktie jetzt für 0€ handeln
MoHelus Pharma welcomes White House order on psychedelic therapies4
MoHelus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions3
MoCybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research12
DoCybin Inc (2): Cybin appoints Kramer senior VP, medical affairs3
DoCYBIN INC. - 6-K, Report of foreign issuer3
DoHelus Pharma Appoints Dr. Ken Kramer as SVP, Medical Affairs5
DoHelus Pharma appoints Ken Kramer as medical affairs head1
DoHelus Pharma beruft Ken Kramer zum neuen Leiter Medical Affairs5
DoHelus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs171Dr. Kramer's 25 years' of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and TORONTO...
► Artikel lesen
13.04.Helus Pharma stock initiated at Buy by TD Cowen on MDD data11
13.03.Cybin Inc (2): Cybin appoints Conwell as chief people officer24
12.03.CYBIN INC. - 6-K, Report of foreign issuer15
12.03.Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer271Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industryAppointment supports Helus Pharma's continued maturation as the company...
► Artikel lesen
05.03.Cybin Inc (2): Cybin talks HLP004 phase 2 study results40
05.03.Jefferies reiterates Helus Pharma stock rating on anxiety data45
05.03.Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints59
05.03.Helus posts mid-stage trial data for anxiety disorder therapy39
Weiter >>
85 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,6